Literature DB >> 17475640

The F gene of rodent brain-adapted mumps virus is a major determinant of neurovirulence.

Ken Lemon1, Bertus K Rima, Stephen McQuaid, Ingrid V Allen, W Paul Duprex.   

Abstract

Prior to the introduction of live-attenuated vaccines, mumps virus (MuV) was the leading cause of virus-induced meningitis. Although vaccination has been effective at controlling the disease, the use of insufficiently attenuated strains has been associated with high rates of aseptic meningitis in vaccinees. The molecular basis of MuV attenuation is poorly understood, and no reliable molecular markers of virulence have been identified. In this study, reverse genetics has been used to identify molecular determinants of MuV neuropathogenesis. Recombinant viruses, containing the envelope-associated genes from the Kilham (MuV(KH)) rodent brain-adapted strain of MuV, were generated in the Jeryl Lynn 5 (MuV(JL5)) vaccine strain background. The syncytium phenotypes of the recombinant viruses on Vero cells differed depending on the source of the fusion (F) and hemagglutinin-neuraminidase (HN) glycoproteins, with heterologous combinations showing either an increase or a decrease in the level of cell fusion compared to that of the homologous parental combinations. This was confirmed by transiently cotransfecting eukaryotic F and HN glycoprotein expression constructs. A Lewis rat model that discriminates between neurovirulent and nonneurovirulent MuV strains based on the extent of hydrocephalus induced in the rat brain after intracerebral inoculation was used to assess the phenotype of the recombinant viruses. Expression of the matrix (M), small hydrophobic (SH), or HN gene in isolation did not confer a neurovirulent phenotype. Expression of the F gene of the neurovirulent strain alone was sufficient to induce significant levels of hydrocephalus. Coexpression of the homologous HN gene led to a marginal increase in the level of hydrocephalus.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17475640      PMCID: PMC1951292          DOI: 10.1128/JVI.00266-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

1.  MULTIPLICATION OF TWO KINDS OF INFLUENZA A2 VIRUS PARTICLES IN MONKEY KIDNEY CELLS.

Authors:  P W CHOPPIN
Journal:  Virology       Date:  1963-11       Impact factor: 3.616

2.  Mumps epidemic--United kingdom, 2004-2005.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2006-02-24       Impact factor: 17.586

3.  The Urabe AM9 mumps vaccine is a mixture of viruses differing at amino acid 335 of the hemagglutinin-neuraminidase gene with one form associated with disease.

Authors:  E G Brown; K Dimock; K E Wright
Journal:  J Infect Dis       Date:  1996-09       Impact factor: 5.226

4.  Nucleotide sequence at position 1081 of the hemagglutinin-neuraminidase gene in the mumps Urabe vaccine strain.

Authors:  M A Afzal; P J Yates; P D Minor
Journal:  J Infect Dis       Date:  1998-01       Impact factor: 5.226

5.  Identification of amino acids involved in the sialidase activity of the mumps virus hemagglutinin-neuraminadase protein.

Authors:  M N Waxham; J Aronowski
Journal:  Virology       Date:  1988-11       Impact factor: 3.616

6.  Virulence and persistence of three prototype strains of mumps virus in newborn hamsters.

Authors:  J S Wolinsky; W G Stroop
Journal:  Arch Virol       Date:  1978       Impact factor: 2.574

7.  Evaluation of a neonatal rat model for prediction of mumps virus neurovirulence in humans.

Authors:  S A Rubin; M Pletnikov; R Taffs; P J Snoy; D Kobasa; E G Brown; K E Wright; K M Carbone
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

8.  Changes in mumps virus gene sequence associated with variability in neurovirulent phenotype.

Authors:  Steven A Rubin; Georgios Amexis; Mikhail Pletnikov; Zongqi Li; Jacqueline Vanderzanden; Jeremy Mauldin; Christian Sauder; Tahir Malik; Konstantin Chumakov; Kathryn M Carbone
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

9.  [Enzyme activity of the neuraminidase from various strains of the influenza A virus].

Authors:  L A Mazhul'; O N Ageeva
Journal:  Vopr Virusol       Date:  1983 Jan-Feb

10.  The reactions of monoclonal antibodies with structural proteins of mumps virus.

Authors:  C Orvell
Journal:  J Immunol       Date:  1984-05       Impact factor: 5.422

View more
  21 in total

Review 1.  Mumps: an Update on Outbreaks, Vaccine Efficacy, and Genomic Diversity.

Authors:  Eugene Lam; Jennifer B Rosen; Jane R Zucker
Journal:  Clin Microbiol Rev       Date:  2020-02-26       Impact factor: 26.132

2.  The Amino Acid at Position 8 of the Proteolytic Cleavage Site of the Mumps Virus Fusion Protein Affects Viral Proteolysis and Fusogenicity.

Authors:  Sarah Hüttl; Markus Hoffmann; Torsten Steinmetzer; Christian Sauder; Nadine Krüger
Journal:  J Virol       Date:  2020-10-27       Impact factor: 5.103

3.  Generation and propagation of recombinant mumps viruses exhibiting an additional U residue in the homopolymeric U tract of the F gene-end signal.

Authors:  Christian J Sauder; Laurie Ngo; Vahan Simonyan; Yu Cong; Cheryl Zhang; Malen Link; Tahir Malik; Steven A Rubin
Journal:  Virus Genes       Date:  2015-05-12       Impact factor: 2.332

4.  Recombinant canine distemper virus strain Snyder Hill expressing green or red fluorescent proteins causes meningoencephalitis in the ferret.

Authors:  M Ludlow; D T Nguyen; D Silin; O Lyubomska; R D de Vries; V von Messling; S McQuaid; R L De Swart; W P Duprex
Journal:  J Virol       Date:  2012-05-02       Impact factor: 5.103

5.  Gene-specific contributions to mumps virus neurovirulence and neuroattenuation.

Authors:  Christian J Sauder; Cheryl X Zhang; Laurie Ngo; Kellie Werner; Ken Lemon; W Paul Duprex; Tahir Malik; Kathryn Carbone; Steven A Rubin
Journal:  J Virol       Date:  2011-05-04       Impact factor: 5.103

6.  Prime-boost vaccination with recombinant mumps virus and recombinant vesicular stomatitis virus vectors elicits an enhanced human immunodeficiency virus type 1 Gag-specific cellular immune response in rhesus macaques.

Authors:  R Xu; F Nasar; S Megati; A Luckay; M Lee; S A Udem; J H Eldridge; M A Egan; E Emini; D K Clarke
Journal:  J Virol       Date:  2009-07-22       Impact factor: 5.103

7.  A point mutation, E95D, in the mumps virus V protein disengages STAT3 targeting from STAT1 targeting.

Authors:  Mamta Puri; Ken Lemon; W Paul Duprex; Bertus K Rima; Curt M Horvath
Journal:  J Virol       Date:  2009-04-22       Impact factor: 5.103

8.  A single nucleotide change in the mumps virus F gene affects virus fusogenicity in vitro and virulence in vivo.

Authors:  Tahir Malik; Christian Sauder; Candie Wolbert; Cheryl Zhang; Kathryn M Carbone; Steven Rubin
Journal:  J Neurovirol       Date:  2007-12       Impact factor: 2.643

9.  Genetic variation in the HN and SH genes of mumps viruses: a comparison of strains from mumps cases with and without neurological symptoms.

Authors:  Aili Cui; David W G Brown; Wenbo Xu; Li Jin
Journal:  PLoS One       Date:  2013-04-24       Impact factor: 3.240

10.  Molecular differences between two Jeryl Lynn mumps virus vaccine component strains, JL5 and JL2.

Authors:  Phil Chambers; Bert K Rima; W Paul Duprex
Journal:  J Gen Virol       Date:  2009-08-05       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.